PBM Skeptics Surfacing in the Senate
Posted by James
All of the Medicare bills that Congress seriously considered this past year—be they Republican; Democrat; or, in the case of the Senate, tripartisan (accounting for Independent Jim Jeffords of Vermont)—re-lied on pharmacy benefit management (PBM) companies to one extent or another. Part of the reason why a Medicare drug bill did not pass was a growing discomfort, especially among Democrats, with certain aspects of the PBM model.
Categories: Main
Add comments
A review of six years of hospital data regarding patients with acute myocardial infarction (AMI) shows that the use of aspirin, anti-platelets, and beta blockers has risen steadily in accordance with guidelines suggesting that treatment with these agents lowers mortality. An analysis of data from PharmScope Insights, a free hospital-pharmacy benchmarking program, shows the following trends: 
Do you ever wonder why certain hospital committees get more done than others, or why a P&T committee in one institution seems to be on top of every important detail while others can’t seem to accomplish anything? Does one of your medication-safety programs seem to be going in reverse gear rather than making the progress you had anticipated? Perhaps help is at hand.
Within the last two years, new therapies have been introduced to treat invasive fungal infections: caspofungin acetate (Cancidas®, Merck) and voriconazole (Vfend®, Pfizer). Caspofungin is the first in a new class of drugs called echinocandins that work by inhibiting synthesis of the fungal cell wall. Voriconazole is a new triazole antifungal medication indicated for the primary treatment of acute invasive aspergillosis and as salvage therapy for rare but serious fungal infections caused by the pathogens Scedosporium apiospermum and Fusarium species.
Overview: The Five Factors to Consider